Bridgewater, N.J. – – October 05, 2026 -- Insmed Incorporated (Nasdaq: INSM) announced that Chief Financial Officer Sara Bonstein will step down on October 30, 2026, after nearly seven years in the role, during which the company raised more than $4.2 billion in capital.

Bonstein exits after helping raise $4.2 billion for Insmed

Bonstein will remain CFO through the company's third-quarter 2026 earnings report and will participate in the earnings call on October 29, 2026, before departing the following day. Insmed has launched a search with an executive search firm to identify her successor. The company stated the transition is unrelated to any disagreement over accounting practices, financial statements, internal controls, or operations.

CEO cites path to cash flow positivity in 2026

Chair and CEO Will Lewis said the company is positioned to reach cash flow positivity next year, pointing to a path toward sustained top-line growth and bottom-line profitability. He credited the commercial launch of BRINSUPRI and the broader pipeline as key drivers of the company's next growth phase.

Insmed reaffirms full-year 2026 revenue guidance

The company confirmed its full-year 2026 financial guidance, projecting revenue of $1.25 billion to $1.40 billion for BRINSUPRI (brensocatib) and $450 million to $470 million for ARIKAYCE (amikacin liposome inhalation suspension). Both products are expected to deliver meaningful revenue this year, with Insmed citing substantial growth ahead through its commercial portfolio and therapeutic pipeline.

Third-quarter results call set for October 29

Insmed will release third-quarter 2026 financial results on Thursday, October 29, 2026, followed by a conference call for investors at 8:00 a.m. ET the same day. A replay will remain accessible through November 5, 2026, and the webcast will be archived for 90 days on the company's investor relations site.